bpc-157 and ipamorelin bpc 157 intramuscular Ipamorelin-CJC 1295 Therapy in Asheville, NC A Shoulder Surgeon's Six Rules

Until comprehensive carcinogenicity studies are completed, individuals with active cancer, cancer history, or high genetic cancer risk should avoid BPC-157

Standard human dosing protocols based on animal studies suggest 0.25-0.5 mg daily via subcutaneous injection for 4-8 weeks

After starting BPC-157, within two weeks pain levels and overall function improved by an estimated 70 percent, enabling sleep without pain and significantly improved range of motion

this is not very common, but if it happens, sitting or lying down for a few minutes post-injection can help

BPC-157 has been observed to have analgesic (pain-relieving) properties